Opexa Shares Recommendation from Advisory Firms to Shareholders

Opexa Therapeutics (NASDAQ:OPXA) announced the recommendation it received for its shareholders from two advisory firms on matters related to their next meeting.
As quoted in the press release:

Opexa Therapeutics announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Opexa shareholders vote “FOR” the proposed merger with Acer Therapeutics Inc. and the related proposals in the Company’s proxy statement/prospectus/information statement for the special meeting of its shareholders to be held on September 19, 2017 at 9:00 a.m. Pacific Time.
ISS and Glass Lewis are widely recognized as leading independent voting and corporate governance advisory firms. Their analysis and recommendations are relied on by many major institutional investment firms, mutual funds, and fiduciaries throughout North America.
In its report, ISS stated, among other things, that “A vote FOR this proposal is warranted. The reverse merger with Acer Therapeutics appears to be the most viable alternative to shareholders considering the company’s financial condition and its future prospects as a standalone entity.”

Click here to read the full press release.
 

Source: www.accesswire.com